Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 231

1.

Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis.

Soret P, Vandenborght LE, Francis F, Coron N, Enaud R, Avalos M, Schaeverbeke T, Berger P, Fayon M, Thiebaut R, Delhaes L; Mucofong Investigation Group.

Sci Rep. 2020 Feb 27;10(1):3589. doi: 10.1038/s41598-020-60015-4.

2.

Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM).

Ramiro S, Landewé RB, van der Heijde D, Sepriano A, FitzGerald O, Ostergaard M, Homik J, Elkayam O, Thorne JC, Larche M, Ferraciolli G, Backhaus M, Boire G, Combe B, Schaeverbeke T, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel AG, Allaart CF, Barnabe C, Bingham CO, Tak PP, van Schaardenburg D, Hammer HB, Dadashova R, Hutchings E, Paschke J, Maksymowych WP.

Ann Rheum Dis. 2020 Apr;79(4):453-459. doi: 10.1136/annrheumdis-2019-216819. Epub 2020 Feb 24.

PMID:
32094157
3.

Decreased CCN3 in Systemic Sclerosis Endothelial Cells Contributes to Impaired Angiogenesis.

Henrot P, Moisan F, Laurent P, Manicki P, Kaulanjan-Checkmodine P, Jolivel V, Rezvani HR, Leroy V, Picard F, Boulon C, Schaeverbeke T, Seneschal J, Lazaro E, Taïeb A, Truchetet ME, Cario M.

J Invest Dermatol. 2020 Jan 16. pii: S0022-202X(20)30016-6. doi: 10.1016/j.jid.2019.11.026. [Epub ahead of print]

PMID:
31954725
4.

[Toxicities of immune checkpoint inhibitors and their management].

Kostine M, Marabelle A, Schaeverbeke T, Kfoury M.

Med Sci (Paris). 2019 Dec;35(12):949-956. doi: 10.1051/medsci/2019191. Epub 2020 Jan 6. French.

PMID:
31903899
5.

Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.

Kostine M, Truchetet ME, Schaeverbeke T.

Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii68-vii74. doi: 10.1093/rheumatology/kez295.

6.

A simplified radiographic score effectively predicts radiographic progression of early arthritis in a large nationwide French cohort.

Carvajal Alegria G, Milin M, Gandjbakhch F, Saraux A, Bailly F, Jousse-Joulin S, Schaeverbeke T, Lukas C, Foltz V, Fautrel B, Devauchelle-Pensec V.

Rheumatology (Oxford). 2019 Oct 19. pii: kez450. doi: 10.1093/rheumatology/kez450. [Epub ahead of print]

PMID:
31628807
7.

Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort.

Sepriano A, Ramiro S, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Elkayam O, Thorne JC, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Schaeverbeke T, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Berner Hammer H, Paschke J, Dadashova R, Hutchings E, Landewé R, Maksymowych WP.

J Rheumatol. 2019 Sep 15. pii: jrheum.190303. doi: 10.3899/jrheum.190303. [Epub ahead of print]

PMID:
31523049
8.

Role of good oral hygiene on clinical evolution of rheumatoid arthritis: a randomized study nested in the ESPOIR cohort.

Mariette X, Perrodeau E, Verner C, Struillou X, Picard N, Schaeverbeke T, Constantin A, Ravaud P, Bouchard P.

Rheumatology (Oxford). 2019 Sep 3. pii: kez368. doi: 10.1093/rheumatology/kez368. [Epub ahead of print]

PMID:
31504982
9.

Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA.

Maksymowych WP, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Lambert RG, Elkayam O, Ramiro S, Thorne JC, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Schaeverbeke T, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Berner Hammer H, Paschke J, Dadashova R, Hutchings E, Sepriano A, Landewé R.

J Rheumatol. 2019 Sep 1. pii: jrheum.190302. doi: 10.3899/jrheum.190302. [Epub ahead of print]

PMID:
31474600
10.

Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR).

Ramos-Casals M, Maria A, Suárez-Almazor ME, Lambotte O, Fisher BA, Hernández-Molina G, Guilpain P, Pundole X, Flores-Chávez A, Baldini C, Bingham Iii CO, Brito-Zerón P, Gottenberg JE, Kostine M, Radstake TRD, Schaeverbeke T, Schulze-Koops H, Calabrese L, Khamashta MA, Mariette X; ICIR.

Clin Exp Rheumatol. 2019 May-Jun;37 Suppl 118(3):114-122. Epub 2019 Aug 28.

11.

Two-year abatacept retention rate in clinical practice in the French ACTION cohort.

Mariette X, Schaeverbeke T, Gaudin P, Chartier M, Heitzmann J, Vannier-Moreau V, Hilliquin P, Cantagrel A.

Joint Bone Spine. 2019 Nov;86(6):753-759. doi: 10.1016/j.jbspin.2019.07.006. Epub 2019 Jul 25.

PMID:
31352138
12.

Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients.

Gossec L, Soubrier M, Foissac F, Molto A, Richette P, Beauvais C, Ruyssen-Witrand A, Perdriger A, Chary-Valckenaere I, Mouterde G, Dernis E, Euller-Ziegler L, Flipo RM, Gilson M, Guis S, Mariette X, Pouplin S, Marhadour T, Schaeverbeke T, Sordet C, Fayet F, Dougados M.

RMD Open. 2019 Jun 14;5(2):e000914. doi: 10.1136/rmdopen-2019-000914. eCollection 2019.

13.

Intestinal Inflammation in Children with Cystic Fibrosis Is Associated with Crohn's-Like Microbiota Disturbances.

Enaud R, Hooks KB, Barre A, Barnetche T, Hubert C, Massot M, Bazin T, Clouzeau H, Bui S, Fayon M, Berger P, Lehours P, Bébéar C, Nikolski M, Lamireau T, Delhaes L, Schaeverbeke T.

J Clin Med. 2019 May 10;8(5). pii: E645. doi: 10.3390/jcm8050645.

14.

Is self-assessment by patients of disease activity acceptable over the long term in rheumatoid arthritis? A 3-year follow-up of 771 patients.

Gossec L, Fayet F, Soubrier M, Foissac F, Molto A, Richette P, Beauvais C, Ruyssen-Witrand A, Perdriger A, Chary-Valckenaere I, Mouterde G, Dernis E, Euller-Ziegler L, Flipo RM, Gilson M, Balandraud N, Mariette X, Pouplin S, Marhadour T, Schaeverbeke T, Sordet C, Dougados M.

Rheumatology (Oxford). 2019 Aug 1;58(8):1498-1499. doi: 10.1093/rheumatology/kez094. No abstract available.

PMID:
30915463
15.

The effect of periodontal treatment on patients with rheumatoid arthritis: The ESPERA randomised controlled trial.

Monsarrat P, Fernandez de Grado G, Constantin A, Willmann C, Nabet C, Sixou M, Cantagrel A, Barnetche T, Mehsen-Cetre N, Schaeverbeke T, Arrivé E, Vergnes JN; ESPERA Group.

Joint Bone Spine. 2019 Oct;86(5):600-609. doi: 10.1016/j.jbspin.2019.02.006. Epub 2019 Feb 26.

PMID:
30822490
16.

Adult-onset Still's disease biological treatment strategy may depend on the phenotypic dichotomy.

Vercruysse F, Barnetche T, Lazaro E, Shipley E, Lifermann F, Balageas A, Delbrel X, Fautrel B, Richez C, Schaeverbeke T, Truchetet ME.

Arthritis Res Ther. 2019 Feb 12;21(1):53. doi: 10.1186/s13075-019-1838-6.

17.

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.

Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, Flipo RM, Saraux A, Schaeverbeke T, Sibilia J, Soubrier M, Vittecoq O, Baron G, Constantin A, Ravaud P, Mariette X; French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries.

BMJ. 2019 Jan 24;364:l67. doi: 10.1136/bmj.l67.

18.

'To switch or not to switch': the missing piece in the puzzle of biosimilar literature?

Scherlinger M, Schaeverbeke T.

Ann Rheum Dis. 2020 Apr;79(4):e36. doi: 10.1136/annrheumdis-2018-214908. Epub 2019 Jan 4. No abstract available.

PMID:
30610068
19.

OX40L/OX40 axis impairs follicular and natural Treg function in human SLE.

Jacquemin C, Augusto JF, Scherlinger M, Gensous N, Forcade E, Douchet I, Levionnois E, Richez C, Lazaro E, Duffau P, Truchetet ME, Seneschal J, Couzi L, Pellegrin JL, Viallard JF, Schaeverbeke T, Pascual V, Contin-Bordes C, Blanco P.

JCI Insight. 2018 Dec 20;3(24). pii: 122167. doi: 10.1172/jci.insight.122167.

20.

[Biosimilars in France, to understand the stakes in order to use them well].

Scherlinger M, Pellegrin JL, Germain V, Lazaro E, Duffau P, Schaeverbeke T; FHU ACRONIM.

Rev Med Interne. 2019 Jan;40(1):5-8. doi: 10.1016/j.revmed.2018.10.383. Epub 2018 Nov 3. French. No abstract available.

PMID:
30396704
21.

Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect.

Germain V, Scherlinger M, Barnetche T, Schaeverbeke T; Fédération Hospitalo-universitaire ACRONIM.

Ann Rheum Dis. 2020 Jan;79(1):e11. doi: 10.1136/annrheumdis-2018-214374. Epub 2018 Oct 23. No abstract available.

PMID:
30352888
22.

MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.

Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, Tsuchiya N, Rojas-Serrano J, González-Pérez MI, Mejía M, Buendía-Roldán I, Falfán-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, Antoniou K, van Moorsel CHM, van der Vis J, de Man YA, Grutters JC, Wang Y, Borie R, Wemeau-Stervinou L, Wallaert B, Flipo RM, Nunes H, Valeyre D, Saidenberg-Kermanac'h N, Boissier MC, Marchand-Adam S, Frazier A, Richette P, Allanore Y, Sibilia J, Dromer C, Richez C, Schaeverbeke T, Lioté H, Thabut G, Nathan N, Amselem S, Soubrier M, Cottin V, Clément A, Deane K, Walts AD, Fingerlin T, Fischer A, Ryu JH, Matteson EL, Niewold TB, Assayag D, Gross A, Wolters P, Schwarz MI, Holers M, Solomon JJ, Doyle T, Rosas IO, Blauwendraat C, Nalls MA, Debray MP, Boileau C, Crestani B, Schwartz DA, Dieudé P.

N Engl J Med. 2018 Dec 6;379(23):2209-2219. doi: 10.1056/NEJMoa1801562. Epub 2018 Oct 20.

23.

Response to: 'Checkpoint inhibitors and arthritis: seeking balance between victories and defeats' by Moura and Moura.

Schaeverbeke T, Kostine M.

Ann Rheum Dis. 2019 Sep;78(9):e92. doi: 10.1136/annrheumdis-2018-213906. Epub 2018 Aug 12. No abstract available.

PMID:
30100560
24.

Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4).

Scherlinger M, Langlois E, Germain V, Schaeverbeke T.

Semin Arthritis Rheum. 2019 Apr;48(5):927-932. doi: 10.1016/j.semarthrit.2018.07.005. Epub 2018 Jul 20.

PMID:
30093238
25.

Reply to the comment of Alkan Melikoglu 'Joint manifestations can provide diagnostic clues in Morquio syndrome, a case report'.

Mitrovic S, Gouze H, Schaeverbeke T, Gossec L, Fautrel B.

Joint Bone Spine. 2019 Jan;86(1):123-124. doi: 10.1016/j.jbspin.2018.06.016. Epub 2018 Jul 29. No abstract available.

PMID:
30064008
26.

Reply.

Truchetet ME, Schaeverbeke T.

Arthritis Rheumatol. 2018 Dec;70(12):2097-2098. doi: 10.1002/art.40677. Epub 2018 Oct 27. No abstract available.

27.

Response to: 'Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors' by Delyon et al.

Kostine M, Schaeverbeke T; FHU-ACRONIM.

Ann Rheum Dis. 2019 Aug;78(8):e83. doi: 10.1136/annrheumdis-2018-213895. Epub 2018 Jul 27. No abstract available.

PMID:
30054370
28.

Response to: 'Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1' by Michot et al and 'Checkpoint inhibitor-associated immune arthritis' by Arnaud et al.

Kostine M, Richez C, Schaeverbeke T; FHU- ACRONIM.

Ann Rheum Dis. 2019 Jul;78(7):e69. doi: 10.1136/annrheumdis-2018-213691. Epub 2018 Jun 22. No abstract available.

PMID:
29934372
29.

Response to: 'Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor' by Chan and Bass.

Kostine M, Dousset L, Schaeverbeke T; FHU-ACRONIM.

Ann Rheum Dis. 2019 Jul;78(7):e71. doi: 10.1136/annrheumdis-2018-213682. Epub 2018 Jun 20. No abstract available.

PMID:
29925509
30.

Impact of systemic sclerosis oral manifestations on patients' health-related quality of life: A systematic review.

Smirani R, Truchetet ME, Poursac N, Naveau A, Schaeverbeke T, Devillard R.

J Oral Pathol Med. 2018 Oct;47(9):808-815. doi: 10.1111/jop.12739. Epub 2018 Jul 5.

PMID:
29855076
31.

Assessment of vertebral microarchitecture in overt and mild Cushing's syndrome using trabecular bone score.

Vinolas H, Grouthier V, Mehsen-Cetre N, Boisson A, Winzenrieth R, Schaeverbeke T, Mesguich C, Bordenave L, Tabarin A.

Clin Endocrinol (Oxf). 2018 Aug;89(2):148-154. doi: 10.1111/cen.13743. Epub 2018 Jun 8.

PMID:
29781519
32.

Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study.

Loustau C, Rosine N, Forien M, Ottaviani S, Juge PA, Lioté F, Bardin T, Richette P, Dieudé P, Richez C, Bannwarth B, Schaeverbeke T, Ea HK, Truchetet ME.

Joint Bone Spine. 2018 Dec;85(6):755-760. doi: 10.1016/j.jbspin.2018.03.015. Epub 2018 Apr 11.

PMID:
29654950
33.

Microbiota Composition May Predict Anti-Tnf Alpha Response in Spondyloarthritis Patients: an Exploratory Study.

Bazin T, Hooks KB, Barnetche T, Truchetet ME, Enaud R, Richez C, Dougados M, Hubert C, Barré A, Nikolski M, Schaeverbeke T.

Sci Rep. 2018 Apr 3;8(1):5446. doi: 10.1038/s41598-018-23571-4.

34.

Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI).

Schaeverbeke T, Pham T, Richez C, Wendling D.

Joint Bone Spine. 2018 Jul;85(4):399-402. doi: 10.1016/j.jbspin.2018.03.002. Epub 2018 Mar 21. No abstract available.

PMID:
29574143
35.

Additional response to the correspondence: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and Bennuci.

Scherlinger M, Schaeverbeke T.

Ann Rheum Dis. 2019 Apr;78(4):e26. doi: 10.1136/annrheumdis-2018-213342. Epub 2018 Mar 13. No abstract available.

PMID:
29535122
36.

The Mycobiome: A Neglected Component in the Microbiota-Gut-Brain Axis.

Enaud R, Vandenborght LE, Coron N, Bazin T, Prevel R, Schaeverbeke T, Berger P, Fayon M, Lamireau T, Delhaes L.

Microorganisms. 2018 Mar 9;6(1). pii: E22. doi: 10.3390/microorganisms6010022. Review.

37.

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.

Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ.

Ann Rheum Dis. 2018 Jun;77(6):840-847. doi: 10.1136/annrheumdis-2017-212608. Epub 2018 Feb 22.

38.

Response to: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and Benucci.

Scherlinger M, Schaeverbeke T.

Ann Rheum Dis. 2019 Apr;78(4):e24. doi: 10.1136/annrheumdis-2018-213021. Epub 2018 Jan 26. No abstract available.

PMID:
29374009
39.

Assessment of subclinical atherosclerosis in systemic lupus erythematosus: A systematic review and meta-analysis.

Henrot P, Foret J, Barnetche T, Lazaro E, Duffau P, Seneschal J, Schaeverbeke T, Truchetet ME, Richez C.

Joint Bone Spine. 2018 Mar;85(2):155-163. doi: 10.1016/j.jbspin.2017.12.009. Epub 2017 Dec 27.

PMID:
29288864
40.

Protective Microbiota: From Localized to Long-Reaching Co-Immunity.

Chiu L, Bazin T, Truchetet ME, Schaeverbeke T, Delhaes L, Pradeu T.

Front Immunol. 2017 Dec 7;8:1678. doi: 10.3389/fimmu.2017.01678. eCollection 2017. Review.

41.

Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the 'ORA' registry.

Nourisson C, Soubrier M, Mulliez A, Baillet A, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Schaeverbeke T, Sibilia J, Vittecoq O, Ravaud P, Gottenberg JE, Mariette X, Tournadre A.

RMD Open. 2017 Nov 1;3(2):e000515. doi: 10.1136/rmdopen-2017-000515. eCollection 2017.

42.

Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance.

Scherlinger M, Germain V, Labadie C, Barnetche T, Truchetet ME, Bannwarth B, Mehsen-Cetre N, Richez C, Schaeverbeke T; FHU ACRONIM.

Joint Bone Spine. 2018 Oct;85(5):561-567. doi: 10.1016/j.jbspin.2017.10.003. Epub 2017 Nov 14.

PMID:
29154920
43.

Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.

Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S, Beylot-Barry M, Daste A, Gross-Goupil M, Lallier J, Ravaud A, Forcade E, Bannwarth B, Truchetet ME, Richez C, Mehsen N, Schaeverbeke T; FHU ACRONIM.

Ann Rheum Dis. 2018 Mar;77(3):393-398. doi: 10.1136/annrheumdis-2017-212257. Epub 2017 Nov 16.

PMID:
29146737
44.

Serum sickness-like disease after switching to biosimilar infliximab.

Scherlinger M, Schaeverbeke T, Truchetet ME; Fédération Hospitalo Universitaire ACRONIM.

Rheumatology (Oxford). 2017 Nov 1;56(11):2032-2034. doi: 10.1093/rheumatology/kex268. No abstract available.

PMID:
28977481
45.

Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE.

Morel J, Constantin A, Baron G, Dernis E, Flipo RM, Rist S, Combe B, Gottenberg JE, Schaeverbeke T, Soubrier M, Vittecoq O, Dougados M, Saraux A, Mariette X, Ravaud P, Sibilia J.

Rheumatology (Oxford). 2017 Oct 1;56(10):1746-1754. doi: 10.1093/rheumatology/kex238.

PMID:
28957557
46.

An open-label, prospective, observational study of the efficacy of bisphosphonate therapy for painful osteoid osteoma.

Bousson V, Leturcq T, Ea HK, Hauger O, Mehsen-Cetre N, Hamzé B, Parlier-Cuau C, Laredo JD, Schaeverbeke T, Orcel P.

Eur Radiol. 2018 Feb;28(2):478-486. doi: 10.1007/s00330-017-5019-1. Epub 2017 Sep 7.

PMID:
28884296
47.

Association of the Presence of Anti-Carbamylated Protein Antibodies in Early Arthritis With a Poorer Clinical and Radiologic Outcome: Data From the French ESPOIR Cohort.

Truchetet ME, Dublanc S, Barnetche T, Vittecoq O, Mariette X, Richez C, Blanco P, Mahler M, Contin-Bordes C, Schaeverbeke T; Fédération Hospitalo-Universitaire ACRONIM.

Arthritis Rheumatol. 2017 Dec;69(12):2292-2302. doi: 10.1002/art.40237.

48.

Efficacy of baricitinib in the treatment of rheumatoid arthritis.

Richez C, Truchetet ME, Kostine M, Schaeverbeke T, Bannwarth B.

Expert Opin Pharmacother. 2017 Sep;18(13):1399-1407. doi: 10.1080/14656566.2017.1359256. Epub 2017 Jul 27. Review.

PMID:
28737053
49.

Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis.

Juge PA, Borie R, Kannengiesser C, Gazal S, Revy P, Wemeau-Stervinou L, Debray MP, Ottaviani S, Marchand-Adam S, Nathan N, Thabut G, Richez C, Nunes H, Callebaut I, Justet A, Leulliot N, Bonnefond A, Salgado D, Richette P, Desvignes JP, Lioté H, Froguel P, Allanore Y, Sand O, Dromer C, Flipo RM, Clément A, Béroud C, Sibilia J, Coustet B, Cottin V, Boissier MC, Wallaert B, Schaeverbeke T, Dastot le Moal F, Frazier A, Ménard C, Soubrier M, Saidenberg N, Valeyre D, Amselem S; FREX consortium, Boileau C, Crestani B, Dieudé P.

Eur Respir J. 2017 May 11;49(5). pii: 1602314. doi: 10.1183/13993003.02314-2016. Print 2017 May.

50.

Neutrophil-derived mitochondrial DNA promotes receptor activator of nuclear factor κB and its ligand signalling in rheumatoid arthritis.

Contis A, Mitrovic S, Lavie J, Douchet I, Lazaro E, Truchetet ME, Goizet C, Contin-Bordes C, Schaeverbeke T, Blanco P, Rossignol R, Faustin B, Richez C, Duffau P.

Rheumatology (Oxford). 2017 Jul 1;56(7):1200-1205. doi: 10.1093/rheumatology/kex041.

PMID:
28340056

Supplemental Content

Loading ...
Support Center